Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
You currently have no recent searches
Kayyali, Andrea MSN, RN
* High doses of celecoxib produced the greatest cardiovascular risk.
* Adverse events occurred most often in patients with the greatest baseline risk.
Cyclooxygenase-2 inhibitors have been shown in several clinical trials to produce an increased risk of cardiovascular events. In a recent "cross trial safety analysis," researchers evaluated the results of six clinical trials involving celecoxib to compare the risk of cardiovascular events at baseline with those related to three celecoxib regimens.
Solomon and colleagues searched the literature for all randomized, double-blind, placebo-controlled clinical trials using celecoxib for conditions other than arthritis that had a minimum follow-up of three years; four studies met their criteria and two other studies were obtained from unpublished sources. A pooled analysis of the combined data from the six trials included 7,950 patients with a follow-up of 16,070 patient-years. The primary outcome for the statistical analysis was the combination of cardiovascular death, myocardial infarction, stroke, heart failure, and thromboembolic event.
In the analysis based on a given dosage and calculated by individual hazard ratios, the greatest risk (3.1) of cardiovascular events was found for the dosage 400-mg twice daily; an "intermediate risk" (1.8) was attributed to the dosage 200 mg twice daily, and the lowest risk (1.1) was associated with the dosage 400 mg once daily. The total hazard ratio for the primary end point for all dosages combined was 1.6. The researchers also found that patients with the most cardiovascular risk factors at baseline had the greatest risk of celecoxib-induced adverse events.
Andrea Kayyali, MSN, RN
Solomon SD, et al. Circulation 2008;117(16):2104–13.
© 2009 Lippincott Williams & Wilkins, Inc.
Colleague's E-mail is Invalid
Your Name: (optional)
Separate multiple e-mails with a (;).
Thought you might appreciate this item(s) I saw at AJN The American Journal of Nursing.
Send a copy to your email
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some time.
An Existing Folder
A New Folder
The item(s) has been successfully added to "".
Login with your LWW Journals username and password.
Username or Email:
Enter and submit the email address you registered with. An email with instructions to reset your password will be sent to that address.
Link to reset your password has been sent to specified email address.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Save my selection
Article Level Metrics